Top Story- Biocon to set up Rs 715-cr biosimilar facility in Malaysia

28 Oct 2010 Evaluate

Biocon Ltd will set up its first overseas manufacturing and research facility in Malaysia with an initial investment of around Rs 715 crore ($ 160 mn) .The USFDA-compliant plants would be operational by 2014 and make high-end biosimilars and biopharmaceuticals for the global market. It is said to be the biggest biotechnology investment in Malaysia. A large amount (of the present investment) would come from Pfizer's upfront payments ($200 million) and internal accruals. We also got good incentives from the Malaysian government.

In the next phase, Biocon would utilise the facility for production of anti-bodies and other biologics. The facility would also generate employment for close to 500 people in total, starting with 250 to 300 people in phase I. The investment follows a memorandum of agreement signed earlier this year between Biocon and BiotechCorp to manufacture bio-pharmaceutical products and formulations, enable the transfer of knowledge to Malaysia's human capital, and create employment.

crackcrack

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×